Resultado de búsqueda
Annie F. Luetkemeyer (born April 13, 1972, Baltimore, Maryland, U.S.) is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco.
HIV therapeutic strategies, COVID-19 treatment and prevention, Sexually Transmitted Infections, DoxyPEP, Viral hepatitis, Hepatitis C, Hepatitis Elimination. Clinical Trials: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide. Start Date: May 2021.
Annie Luetkemeyer, MD. HIV therapeutic strategies, COVID-19 treatment and prevention, Sexually Transmitted Infections, DoxyPEP, Viral hepatitis, Hepatitis C, Hepatitis Elimination. Open Clinical Studies at SFGH ID division. End Hep C SF. UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses (07/23/2012)
Annie Luetkemeyer. Professor. School of Medicine. [email protected] +1 415 502-5753. Publications: . Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. The Journal of infectious diseases.
Annie Luetkemeyer, MD, is a UCSF infectious disease physician and researcher who leads clinical trials of promising therapies for COVID-19, including remdesivir and convalescent plasma. She also cares for HIV and hepatitis C patients and advocates for vulnerable populations affected by the pandemic.
Comparison of Quantiferon to Conventional Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection (LTBI) in HIV Positive Subjects. Mentored Scientist Award, Spring 2005.
Annie Luetkemeyer, MD, professor of infectious diseases at UCSF, is an expert on the treatment of viral infections. On March 24, 2020, Robert Wachter, MD, chair of the Department of Medicine at UCSF, interviewed her on the evidence behind ...
